EpiPen Rival Set For Return

EpiPen competitor alternative Auvi-Q returning soon

The Auvi-Q, which was launched by Sanofi in January 2013, has a voice prompt system that talks its user through the process of delivering epinephrine in a manner somewhat similar to the EpiPen.

Mylan has since taken steps to reign in the cost by offering a 50% discount to patients who are uninsured or underinsured, as well as saying it will offer a generic version at half price.

Auvi-Q, an epinephrine auto-injector considered an alternative to the EpiPen, will be reintroduced in the USA market in early 2017, according to its manufacturer.

Virginia-based Kaléo, Inc., has announced that it will reintroduce its Auvi-Q (epinephrine injection, USP) auto-injector to the US market in the first half of 2017.

Kaleo's injector, called Auvi-Q, was recalled from USA sales about a year ago over potential malfunctions that could give patients the wrong dose of drug.

Kaleo Inc announced on Wednesday plans for a US relaunch of its Auvi-Q injector in early 2017.

Mylan Specialty, the maker of EpiPen, came under fire from members of Congress and parents beginning in August for its large price increases.

The device contains the same epinephrine drug that's in Mylan Pharmaceuticals' EpiPen. Still, Williamson says the company is doing all it can to create a lower-cost option for patients. News of Kaléo's return sent Mylan shares down more than 2 percent in midday trading.

Kaleo did not offer information on how much Auvi-Q would cost, but said it is committed to affordability. The Auvi-Q, like the EpiPen, is created to inject an emergency dose of epinephrine in the event of a severe allergic reaction.

Unlike the EpiPen, Auvi-Q is roughly the shape and size of a deck of cards, and comes with pre-recorded audio instructions that can assist patients by talking through the step-by-step use of the device. Sanofi later sold the rights back to Kaleo, which says it fixed the problem and invested in new technology and quality systems to boost reliability. The product is made on a robotic assembly line that is entirely automated and includes over 100 quality checks for each product, the company said.

"We're working with multiple stakeholders including wholesalers, pharmacy benefit managers, insurers, etc., to establish a comprehensive access program", he said.

Related news: